Study On The Clinical Efficacy And Cytokines Of Resuvastatin On Adult Obese Patients With Asthma

Objective:To evaluate the clinical efficacy of resuvastatin on adult obese patients with asthma,Serum adiponectin,tumor necrosis factor-?(TNF-?)and interleukin-6(IL-6)were detected to investigate the possible therapeutic mechanism.Methods: We use a case-control design study method.From January 2017-May 2018,In Qingdao municipal hospital outpatient and ward,44 adult obese patients with asthma(non-acute phase)were randomly divided into 2 groups.Among them,there were 10 males and 12 females in the control group(22 cases),and 9 males and 13 females in the experimental group(22 cases).The control group received a therapeutic lifestyle change(TLC),and inhaled budesonide/formoterol dry powder inhaler or sametrotikasone powder inhaler,once a time,twice a day,the course of treatment is 8 weeks;The experimental group was given rosuvastatin 10 mg once a night on the basis of the control group,and the course of treatment was 8 weeks;During clinical observation,salbutamol aerosol was administered to relieve acute exacerbation if necessary.Adverse drug reactions were monitored during treatment.There were no significant differences in the general data of age,sex,duration of disease,BMI,and inhalation application,serum lipid level between the two groups(P>0.05).Serum total cholesterol(TC),forced expiratory volume in one second(FEV1),forced vital capacity(FVC),Immunoglobulin E(IgE)and eosinophils(EOS)in the blood were detected before and after treatment,The expression level of Serum adiponectin,tumor necrosis factor-?(TNF-?)and interleukin-6(IL-6)was determined by ELISA.The operation is carried out in strict accordance with the instructions.The data of the control group and the experimental group were statistically analyzed with SPSS19.0 software,Normality and homogeneity of variance were detected for each group of data.Comparisons were made using paired and independent sample T tests;P < 0.05 was considered statistically significant.Results:The FVC,ACT score,and serum adiponectin expression levels in the experimental group were higher than those before treatment(P < 0.05).The levels of TC,EOS,peripheral venous blood IgE,serum TNF-?,IL-6 were lower than before treatment(P<0.05).There was no significant difference in FEV1 levels after treatment in comparision with that before treatment in the experimental group(P>0.05).The levels of TC,EOS,serum IL-6 in the control group were lower than those before treatment(P<0.05).There was no significant difference in FEV1,FVC,ACT score,peripheral venous blood IgE,serum adiponectin and TNF-?levels after treatment in comparision with that before treatment in the control group(P>0.05).There were significant differences in FEV1,FVC,ACT scores,IgE levels,serum adiponectin and TNF-? levels after treatment in two groups(P>0.05).Conclusion:1.Rosuvastatin can improve the clinical symptoms of adult obese patients with asthma,partially improve lung function,reduce airway inflammation in patients,and have less adverse reactions.adult obese patients with asthma may be the dominant group of rosuvastatin in the treatment of asthma.2.Rosuvastatin can increase adiponectin level and decrease the level of IL-6 and TNF-?,which may be a mechanism of rosuvastatin in the treatment of adult obese patients with asthma and hyperlipidemia.